Inclusion Criteria:

All of the following must apply:

- Histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction
that is:

1. completely resected with negative margins

2. Stage T3,4 and/or N1,2 patients who have undergone a D2 nodal dissection can be
entered on the study at the discretion of the treating clinician.

- Age greater than or equal to 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

- Adequate organ function defined as follows:

- Bone marrow: Haemoglobin greater than or equal to 90 g/L; Neutrophil count
greater than or equal to 1.5 x 10^9 /L; Platelet count greater than or equal to
100 x 10^9 /L

- Hepatic: Serum bilirubin less than or equal to 1.5 x ULN; AST and/or ALT less
than or equal to 3.0 x ULN;

- Renal: Serum creatinine less than or equal to 0.150 mmol/L, and calculated
creatinine clearance greater than or equal to 50mL/min.

- Adequate oral nutrition (intake greater than or equal to 1500 calories/day). This is
to be assessed by a dietician prior to commencing treatment.

- Disease which can be radically treated to 45 Gy with standard fractionation.

- Patient able to be treated with infusional 5-fluorouracil (5-FU) and ECF
chemotherapy.

- Written informed consent

Exclusion Criteria:

None of the following must apply:

- Evidence of metastatic disease.

- Prior chemotherapy or radiotherapy

- Patients with other significant underlying medical conditions that may be aggravated
by the study treatment or are not controlled.

- Pregnant or lactating females or female patients of childbearing potential who have
not been surgically sterilized or are without adequate contraceptive measures.

- Cardiac failure (relevant to the use of epirubicin):

- Patients with myocardial infarction within the last 6 months;

- Patients with New York Heart Association class III/IV congestive heart failure